HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Oncolytics Biotech (NASDAQ:ONCY) and maintained a price target of $5.
September 19, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Oncolytics Biotech and maintained a $5 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Oncolytics Biotech's future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100